Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b switch study of emtricitabine/rilpivirine/tenofovir alafenamide versus continued emtricitabine/rilpivirine/tenofovir disoproxil in HIV-1 infection
2014-004545-27Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of emtricitabine, rilpivirine, tenofovir alafenamide and tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Virologic non-inferiority after switch to FTC/RPV/TAF versus continued FTC/RPV/TDF. Started Jan 2015; status: completed.
02
Drugs
emtricitabinerilpivirinetenofovir alafenamidetenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2014-004545-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004545-27.